Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Invex Therapeutics Ltd. ( (AU:IXC) ) is now available.
Invex Therapeutics Ltd announced new findings from its collaboration with Tessara Therapeutics, showing that Exenatide significantly reduces neurofilament light chain expression, a marker of neuronal damage, in Alzheimer’s Disease models. This suggests Exenatide’s potential in mitigating early neurodegenerative processes and enhancing its therapeutic value in treating Alzheimer’s Disease, despite uncertainties regarding the continuation of the Tessara collaboration due to potential board changes.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company focused on the development and commercialization of Exenatide for neurological conditions related to raised intracranial pressure.
Average Trading Volume: 65,477
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$8.64M
Find detailed analytics on IXC stock on TipRanks’ Stock Analysis page.